3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
2
Unknown
1
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Motor Activity
13
Neoplasms
9
Lung Neoplasms
3
Breast Neoplasms
3
Stomach Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Disease
2
Urinary Bladder Neoplasms
1
Rectal Neoplasms
1
Psychological Well-Being
1
Prostatic Neoplasms
1
Personal Satisfaction
1
Peripheral Nervous System Diseases
1
Pelvic Floor Disorders
1
Ovarian Neoplasms
1
Obesity
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Muscular Atrophy
1
Mesothelioma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Esophageal Neoplasms
1
Edema
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Cardiotoxicity
1
Carcinoma, Non-Small-Cell Lung
1
Cancer Patients
1
Cachexia
1
Interventions
trastuzumab deruxtecan
4
Cyclophosphamide
4
pembrolizumab
3
fludarabine
3
Standard of Care
3
Cisplatin
3
Bevacizumab
3
toripalimab
2
sacituzumab govitecan
2
fludarabine phosphate
2
Specimen Handling
2
Radiosurgery
2
Pemetrexed
2
Palliative Care
2
Nivolumab
2
Injections
2
Gemcitabine
2
Fulvestrant
2
Fluorouracil
2
130-nm albumin-bound paclitaxel
2
zimberelimab
1
vedolizumab
1
tislelizumab
1
sintilimab
1
lobaplatin
1
lenvatinib
1
ivosidenib
1
irinotecan sucrosofate
1
exemestane
1
eribulin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Neoplasm Metastasis
×
Exercise
×
Clear all
NCT07521826
2026-04-13
FITCAN
State University of Londrina
Phase NA
Not yet recruiting
78 enrolled